These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 32083570)
21. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127 [TBL] [Abstract][Full Text] [Related]
22. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis. Shi JX; Qin JJ; Ye H; Wang P; Wang KJ; Zhang JY Expert Rev Mol Diagn; 2015 Jun; 15(6):829-52. PubMed ID: 25959246 [TBL] [Abstract][Full Text] [Related]
23. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Chen H; Werner S; Butt J; Zörnig I; Knebel P; Michel A; Eichmüller SB; Jäger D; Waterboer T; Pawlita M; Brenner H Oncotarget; 2016 Mar; 7(13):16420-32. PubMed ID: 26909861 [TBL] [Abstract][Full Text] [Related]
24. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer]. Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769 [TBL] [Abstract][Full Text] [Related]
25. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer. Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923 [TBL] [Abstract][Full Text] [Related]
26. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis. Yang J; Jiao S; Kang J; Li R; Zhang G Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828 [TBL] [Abstract][Full Text] [Related]
27. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer. Fan CW; Kuo YB; Lin GP; Chen SM; Chang SH; Li BA; Chan EC Clin Chim Acta; 2017 Dec; 475():157-163. PubMed ID: 29074220 [TBL] [Abstract][Full Text] [Related]
28. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer]. Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310 [No Abstract] [Full Text] [Related]
30. [Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens]. Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L Zhonghua Fu Chan Ke Za Zhi; 2007 Dec; 42(12):834-9. PubMed ID: 18476518 [TBL] [Abstract][Full Text] [Related]
31. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma. Xu YW; Chen H; Guo HP; Yang SH; Luo YH; Liu CT; Huang XY; Tang XM; Hong CQ; Li EM; Xu LY; Peng YH Gastric Cancer; 2019 May; 22(3):546-557. PubMed ID: 30426295 [TBL] [Abstract][Full Text] [Related]
32. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer. Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X Front Immunol; 2021; 12():698312. PubMed ID: 34489945 [TBL] [Abstract][Full Text] [Related]
33. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537 [TBL] [Abstract][Full Text] [Related]
34. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group. Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776 [TBL] [Abstract][Full Text] [Related]
35. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876 [TBL] [Abstract][Full Text] [Related]
36. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399 [TBL] [Abstract][Full Text] [Related]
37. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755 [TBL] [Abstract][Full Text] [Related]
38. Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Hoshino I; Nagata M; Takiguchi N; Nabeya Y; Ikeda A; Yokoi S; Kuwajima A; Tagawa M; Matsushita K; Satoshi Y; Hideaki S Cancer Sci; 2017 Mar; 108(3):308-315. PubMed ID: 28064445 [TBL] [Abstract][Full Text] [Related]
39. Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies. Da Gama Duarte J; Quigley LT; Young AR; Hayashi M; Miyazawa M; Lopata A; Mancuso N; Mikami M; Behren A; Meeusen E Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681879 [TBL] [Abstract][Full Text] [Related]
40. Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk? Wang M; Liu F; Pan Y; Xu R; Li F; Liu A; Yang H; Duan L; Shen L; Wu Q; Liu Y; Liu M; Liu Z; Hu Z; Chen H; Cai H; He Z; Ke Y EBioMedicine; 2021 Nov; 73():103674. PubMed ID: 34753106 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]